1. Biswal SG, Mehta RD. Cutaneous adverse reactions of chemotherapy in cancer patients: a clinicoepidemiological study. Indian J Dermatol. 2018;63(1):41–6. https://doi.org/10.4103/ijd.IJD_65_17.
2. Ng CY, Chen C-B, Wu M-Y, et al. Anticancer drugs induced severe adverse cutaneous drug reactions: an updated review on the risks associated with anticancer targeted therapy or immunotherapies. J Immunol Res. 2018;17(2018):5376476.
3. Rosen AC, Balagula Y, Raisch DW, et al. Life-threatening dermatologic adverse events in oncology. Anticancer Drugs. 2014;25(2):225–34. https://doi.org/10.1097/CAD.0000000000000032.
4. EMA. Zenapax [prescribing information]. https://www.ema.europa.eu/en/documents/product-information/zenapax-epar-product-information_en.pdf. Accessed 12 May 2020.
5. MPR. Roche discontinues Zenapax injection. Published 22 December, 2009. https://www.empr.com/home/news/roche-discontinues-zenapax-injection/. Accessed 12 May 2020.